BioProtonics has developed Magnetic Resonance Histopathology (MRH), a non-invasive MRI-based diagnostic tool that measures tissue texture at the micro level to enhance early detection of diseases like cancer. This technology integrates seamlessly into standard MRI scans, adding minimal time while providing accurate insights that reduce the need for surgical biopsies and improve patient outcomes.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting diseases like cancer often rely on invasive surgical biopsies, which can be costly, time-consuming, and carry risks for patients. Traditional MRI scans may not always detect subtle tissue changes indicative of early-stage disease, leading to delayed diagnosis and treatment.
Solution
BioProtonics' Magnetic Resonance Histopathology (MRH) is a non-invasive, MRI-based software method that measures tissue texture at the micro level (sub 1mm) to enhance the early detection of diseases. The MRH protocol integrates into standard MRI exams, adding minimal time to the overall procedure. MRH captures novel data about the tissue microarchitecture by targeting specific spatial wavelengths, providing insight into tissue texture and structural differences. The resulting data is then analyzed using advanced AI algorithms, comparing MRH data like a digital biopsy with ground truth biopsy results to identify subtle differences in tissue structure.
Target Audience
The primary users are radiologists and other medical professionals who utilize MRI for disease detection and diagnosis, particularly in the early stages of cancer and other diseases.
Features
- Proprietary MRI pulse sequence captures novel data about tissue microarchitecture.
- Compatible with DICOM protocols for seamless integration with existing medical imaging workflows.
- Adds as little as 90 seconds to a standard MRI scan.
- Advanced AI analysis compares MRH data to ground truth biopsy results for enhanced early diagnosis.
- Provides a non-invasive alternative to surgical biopsies.
- AI analytics are accessed via the BioProtonics Cloud.